SAN FRANCISCO--(BUSINESS WIRE)--A new analysis presented at the American Diabetes Association (ADA) 68th Annual Scientific Sessions showed treatment with JANUVIA™ (sitagliptin), Merck & Co., Inc.'s diabetes medicine, was associated with a 93 percent lower risk of having a confirmed symptomatic hypoglycemic event on a given day (p=0.001) compared to treatment with glipizide, a sulfonylurea. This 52-week intent to treat analysis was based on 37 events in the JANUVIA group (n=588) and 492 events in the glipizide group (n=584). Both agents were added to ongoing metformin therapy in patients with type 2 diabetes and were associated with similar reductions in A1C1 (0.5 percent for JANUVIA and 0.6 percent for glipizide in the intent-to-treat patient population).
